Femasys Inc. (FEMY)
| Market Cap | 27.90M |
| Revenue (ttm) | 1.05M |
| Net Income (ttm) | -14.90M |
| Shares Out | 22.22M |
| EPS (ttm) | -0.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22,119 |
| Open | 1.250 |
| Previous Close | 1.270 |
| Day's Range | 1.240 - 1.290 |
| 52-Week Range | 0.248 - 4.750 |
| Beta | -2.76 |
| Analysts | Strong Buy |
| Price Target | 10.50 (+726.77%) |
| Earnings Date | May 9, 2024 |
About FEMY
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially w... [Read more]
Financial Performance
In 2023, Femasys's revenue was $1.07 million, a decrease of -11.13% compared to the previous year's $1.21 million. Losses were -$14.25 million, 25.0% more than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for FEMY stock is "Strong Buy." The 12-month stock price forecast is $10.5, which is an increase of 726.77% from the latest price.
News
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative
Lee-Sepsick Discussed Company's FemCerv® Endocervical Tissue Sampler and its Role in Cervical Cancer Diagnosis Lee-Sepsick Discussed Company's FemCerv® Endocervical Tissue Sampler and its Role in Cerv...
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council
Lee-Sepsick Discussed Atlanta-Based Biomedical Company's Women's Reproductive Health Products Lee-Sepsick Discussed Atlanta-Based Biomedical Company's Women's Reproductive Health Products
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
-- Recruitment of the commercial team for our infertility portfolio and the pivotal trial of FemBloc ® for permanent non-surgical birth control continues -- ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- F...
Femasys Expands Commercial Management Team with Addition of Experienced New Hires
Team to Drive Strategic Initiatives, Launching Efforts at 2024 ACOG Meeting Team to Drive Strategic Initiatives, Launching Efforts at 2024 ACOG Meeting
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives
ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-offi...
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
Following FDA Clearance of FemaSeed®, Company Secures Capital to Support Commercial Initiatives; Cash Expected to Fund Operations Into 2H 2025 Following FDA Clearance of FemaSeed®, Company Secures Cap...
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
-- CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu to Join Jones Trading Analyst Catherine Novack in a Conversation on Current Treatment Options in Infertility Including FemaSeed® at 1PM ET ...
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
-- In the severe male factor cohort, findings show 24% of women became pregnant after FemaSeed -- -- FemaSeed pregnancy rate by cycle was more than double historic intrauterine insemination (IUI) rate...
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
-- Paving the way forward for the broader commercial availability of FemaSeed, an accessible, safe, and cost effective alternative to IVF -- -- Ongoing uncertainty following recent Alabama Supreme Cou...
Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
-- Femasys readies for the commercial launch of FemaSeed ® in the U.S. amidst the uncertainty following the Alabama Supreme Court Ruling on how to handle embryos used for in vitro fertilization (IVF) ...
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
-- Seasoned sales and marketing executive with 25 years of experience leading public and private healthcare companies throughout various stages of commercialization will lead commercial launch of Fema...
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
ATLANTA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessi...
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
- University of Utah Hospital, Lori Gawron, M.D. of the Obstetrics and Gynecology (OB/GYN) Department, was an instrumental investigator in Femasys' earlier FemBloc study -
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine
- Stanford Medicine, a center with a long tradition of leadership in pioneering gynecological research and innovation, is the second academic center to participate in the FemBloc pivotal trial since e...
Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer
-- Thought leader from top-ranked academic gynecology program to lead clinical and medical affairs at Femasys -- -- Thought leader from top-ranked academic gynecology program to lead clinical and medi...
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch
- Topline results from FemaSeed ® pivotal trial expected in 1H 2024 - - Commercial launch planned for early 2024 - ATLANTA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical ...
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (“Femasys”), a biomedic...
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
- $6.85 million upfront investment provides $23 million total cash runway into second half 2025 - - Financing allows for focused commercial team to bring Femasys' infertility-related products to women...
Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update
- 510(k) product clearance gained for lead product, FemaSeed potentially allowing sooner-than-expected product commercialization -
Femasys Inc. EU MDR Final Audit Successfully Completed
– Completion of the European Union Medical Device Regulation (MDR) final audit is the last step in obtaining an MDR certificate and CE marking, confirming Femasys' compliance with the highest required...
Femasys Inc. Regains Compliance with Nasdaq Listing Requirements
ATLANTA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (Nasdaq: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessi...
Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine
ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessi...
Femasys Inc. MDSAP Surveillance Audit Successfully Completed
– Femasys demonstrates compliance with harmonized regulatory requirements for Australia, Brazil, Japan, Canada and the USA –
Femasys (FEMY) stock price is up 1,250% but there are 2 key risks
The remarkable Femasys (NASDAQ: FEMY) stock price comeback continued on Monday as demand for the shares continued. The shares surged by more than 45% on Friday and gained by another 15% in the pre-mar...
Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate
ATLANTA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, access...